Monte Rosa Therapeutics announced data for MRT-8102, its NEK7-directed molecular glue degrader, showing positive impact on biomarkers linked to atherosclerotic cardiovascular disease
BiotechTV - News
00:00
Monte Rosa’s Basel-Boston Operating Model
Markus Warmuth explains Monte Rosa’s balanced Basel-Boston workforce, collaborative culture, and proximity to major pharmaceutical partners in Basel.
Play episode from 00:42
Transcript
